Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Amicus Therapeutics Stock Quote

Amicus Therapeutics (NASDAQ: FOLD)

Price as of July 12, 2024, 4:00 p.m. ET

Amicus Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
FOLD -20.35% -16.05% -3.43% -28%
S&P +24.51% +86.32% +13.24% +267%

Amicus Therapeutics Company Info

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

News & Analysis

The Fool has written over 100 articles on Amicus Therapeutics.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.